Celgene Corporation to Present at JMP Securities Healthcare Focus Conference and Amgen to Provide New Evidence as Part of a Formal Reconsideration of CMS' National Coverage Determination on ESAs
City of Industry, CA --(www.USEquityNews.com)-- 11/09/2007 - Biotechnology industry alert provided by U.S. Equity News. Celgene Corporation (NASDAQ: CELG) announced recently that its presentation at the JMP Securities Healthcare Focus Conference on Tuesday, November 13, 2007 at 9:00 am EST will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Robert J. Hugin, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
CV Therapeutics, Inc. (NASDAQ: CVTX) announced recently that data from a preclinical study of the selective adenosine A1 agonist tecadenoson, in combination with a low dose of the beta blocker metoprolol, showed increased rate control compared to either agent alone (p<0.05) in an established animal model of atrial fibrillation. Tecadenoson also demonstrated effective rate control at rest and during exercise in this preclinical model. The findings were presented at the American Heart Association Scientific Sessions in Orlando, Florida by Dr. Ulrich Schotten of University Maastricht in the Netherlands.
Amgen (NASDAQ: AMGN) recently announced its intention to submit new evidence to the Centers for Medicare and Medicaid Services (CMS) to support a reconsideration of the agency’s National Coverage Determination (NCD) on Erythropoiesis Stimulating Agents (ESAs). The Company plans to file its request shortly. The oncology community, Amgen, and CMS have worked collaboratively to arrive at consensus-based, patient-centric provisions for most aspects of the NCD.
Emergency Disaster Systems, Inc., a subsidiary of U.S. BioDefense, Inc. (OTCBB: UBDE) assists Certified Emergency Response Teams (CERT) in California by donating supplies. These supplies include emergency blankets, disposable gloves and dust masks. All CERT groups that have not been notified can contact Emergency Disaster Systems by calling (866) MyEDSkit or email cs@myedskit.com to receive their supplies. "We would like to support all fire departments, CERT, and volunteers that are assisting the victims of this tragic event," said David Chin, CEO of U.S. BioDefense.
About U.S. Equity News
U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.
U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com
Contact Information:
U.S. Equity News
Tel: (626) 961-8039
Email: info@usequitynews.com
| EMAIL THIS RELEASE |
Featured Clients
Market News Update